Dyne Therapeutics (NASDAQ: DYN) net income
Dyne Therapeutics reported a net loss of $446.2m for fiscal 2025; in fiscal 2024 it reported a net loss of $317.4m. Earnings per share were −$3.47.
Dyne Therapeutics's best year of the last 7 was fiscal 2019. It reported a loss in 7 of those 7 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$446.2m | — | — | −$3.47 |
| 2024 | −$317.4m | — | — | −$3.37 |
| 2023 | −$235.9m | — | — | −$3.95 |
| 2022 | −$168.1m | — | — | −$3.23 |
| 2021 | −$149.3m | — | — | −$2.93 |
| 2020 | −$59.4m | — | — | — |
| 2019 | −$14.9m | — | — | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Dyne Therapeutics net income compared with its sector
By net income for its latest fiscal year, Dyne Therapeutics ranks 472nd of the 501 US health care companies with a page on Celsmar.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 470th | Vir Biotechnology | −$438.0m | −638.9% |
| 471st | Oscar Health | −$443.2m | −3.8% |
| 472nd | Dyne Therapeutics | −$446.2m | — |
| 473rd | Immunovant | −$505.6m | — |
| 474th | Denali Therapeutics | −$512.5m | — |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Dyne Therapeutics
- How much did Dyne Therapeutics earn in fiscal 2025?
- Dyne Therapeutics reported a net loss of $446.2m for fiscal 2025. In fiscal 2024 it reported a net loss of $317.4m.
- What are the earnings per share of Dyne Therapeutics?
- They were −$3.47 in fiscal 2025, compared with −$3.37 in fiscal 2024.
- Where does Dyne Therapeutics rank in its sector by net income?
- It ranks 472nd of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Dyne Therapeutics come from?
- From the annual report (Form 10-K) that Dyne Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Dyne Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019. More on Dyne Therapeutics: the Dyne Therapeutics page · annual accounts · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.